Artemis Investment Management LLP Has $4.67 Million Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Artemis Investment Management LLP increased its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 398.3% during the 4th quarter, Holdings Channel reports. The fund owned 295,530 shares of the company’s stock after buying an additional 236,224 shares during the quarter. Artemis Investment Management LLP’s holdings in Dr. Reddy’s Laboratories were worth $4,666,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its position in shares of Dr. Reddy’s Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after purchasing an additional 114,294 shares in the last quarter. State Street Corp lifted its holdings in Dr. Reddy’s Laboratories by 1.9% during the third quarter. State Street Corp now owns 909,905 shares of the company’s stock worth $72,292,000 after acquiring an additional 16,641 shares in the last quarter. Fisher Asset Management LLC grew its stake in Dr. Reddy’s Laboratories by 59.4% in the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after acquiring an additional 183,146 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Dr. Reddy’s Laboratories by 30.8% in the third quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock worth $32,530,000 after acquiring an additional 96,339 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Dr. Reddy’s Laboratories by 318.0% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock worth $28,411,000 after acquiring an additional 283,700 shares in the last quarter. Institutional investors and hedge funds own 3.85% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on RDY. Barclays cut their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $14.91 on Monday. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. The firm has a fifty day simple moving average of $14.86 and a 200 day simple moving average of $15.55. Dr. Reddy’s Laboratories Limited has a 1-year low of $13.47 and a 1-year high of $16.89. The stock has a market capitalization of $12.44 billion, a PE ratio of 23.82 and a beta of 0.51.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.